| Literature DB >> 29380952 |
Jennifer C Richards1, Matthew L Racine1, Christopher M Hearon1, Megan Kunkel1, Gary J Luckasen2, Dennis G Larson2, Jason D Allen3,4, Frank A Dinenno1.
Abstract
Dietary nitrate (NO3-) is converted to nitrite (NO2-) and can be further reduced to the vasodilator nitric oxide (NO) amid a low O2 environment. Accordingly, dietary NO3- increases hind limb blood flow in rats during treadmill exercise; however, the evidence of such an effect in humans is unclear. We tested the hypothesis that acute dietary NO3- (via beetroot [BR] juice) increases forearm blood flow (FBF) via local vasodilation during handgrip exercise in young adults (n = 11; 25 ± 2 years). FBF (Doppler ultrasound) and blood pressure (Finapres) were measured at rest and during graded handgrip exercise at 5%, 15%, and 25% maximal voluntary contraction (MVC) lasting 4 min each. At the highest workload (25% MVC), systemic hypoxia (80% SaO2 ) was induced and exercise continued for three additional minutes. Subjects ingested concentrated BR (12.6 mmol nitrate (n = 5) or 16.8 mmol nitrate (n = 6) and repeated the exercise bout either 2 (12.6 mmol) or 3 h (16.8 mmol) postconsumption. Compared to control, BR significantly increased FBF at 15% MVC (184 ± 15 vs. 164 ± 15 mL/min), 25% MVC (323 ± 27 vs. 286 ± 28 mL/min), and 25% + hypoxia (373 ± 39 vs. 343 ± 32 mL/min) and this was due to increases in vascular conductance (i.e., vasodilation). The effect of BR on hemodynamics was not different between the two doses of BR ingested. Forearm VO2 was also elevated during exercise at 15% and 25% MVC. We conclude that acute increases in circulating NO3- and NO2- via BR increases muscle blood flow during moderate- to high-intensity handgrip exercise via local vasodilation. These findings may have important implications for aging and diseased populations that demonstrate impaired muscle perfusion and exercise intolerance.Entities:
Keywords: Dietary nitrate; exercise hyperemia; oxygen consumption
Mesh:
Substances:
Year: 2018 PMID: 29380952 PMCID: PMC5789727 DOI: 10.14814/phy2.13572
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Subject characteristics
| Beet juice group | |
| Male:Female | 6:5 |
| Age (years) | 25 ± 2 |
| BMI (kg/m2) | 23 ± 1 |
| Maximal voluntary contraction (kg) | 35 ± 4 |
| Forearm volume (mL) | 823 ± 106 |
| Placebo group | |
| Male:Female | 5:2 |
| Age (years) | 24 ± 1 |
| BMI (kg/m2) | 23 ± 1 |
| Maximal voluntary contraction (kg) | 42 ± 3 |
| Forearm volume (mL) | 1077 ± 39 |
Figure 1Study Timeline. Following venous catheter insertion and 30 min of quiet rest, participants performed graded handgrip exercise (5%, 15%, 25% maximal voluntary contraction [MVC]) for 4 min at each intensity. During 25% MVC, participants continued performing handgrip exercise for an additional 3 min while they underwent systemic hypoxia (80% SpO2). The blood flow response to graded exercise and hypoxic exercise was assesses in control conditions and following ingestion of 210 or 280 mL of concentrated BR (12.6 mmol nitrate (n = 5) or 16.8 mmol nitrate (n = 6). Participants performed their second bout (beetroot [BR] juice) of exercise either 2 h (12.6 mmol) or 3 h (16.8 mmol) postconsumption. On a separate day and with separate individuals (n = 7), the experimental protocol was repeated with nitrate‐free concentrated BR juice. Venous blood was obtained for and at rest prior to the onset of each exercise trial, and for blood gasses at rest and the end of each exercise intensity during normoxia and hypoxia.
Hemodynamics at rest and during exercise in BR and Placebo Trials
| HR (bpm) | MAP (mmHg) | Brachial artery diameter (mm) | FBF (mL/min) | FVC (mL/min/mmHg) | VO2 (mL/min) | |
|---|---|---|---|---|---|---|
| Control trial | ||||||
| Rest | 60 ± 3 | 87.2 ± 2.0 | 3.8 ± 0.1 | 29.2 ± 4.7 | 33.3 ± 5.0 | 2.2 ± 0.2 |
| 5% MVC | 61 ± 3 | 90.4 ± 2.2 | 3.8 ± 0.1 | 59.4 ± 4.7 | 65.0 ± 3.9 | 6.9 ± 0.6 |
| 15% MVC | 65 ± 3 | 92.1 ± 2.6 | 3.9 ± 0.1 | 164.4 ± 15.1 | 199.6 ± 15.4 | 20.1 ± 2.3 |
| 25% MVC | 70 ± 3 | 98.3 ± 3.0 | 4.0 ± 0.1 | 285.8 ± 28.5 | 288.6 ± 22.5 | 33.9 ± 4.4 |
| 25% MVC + hypoxia | 83 ± 3 | 99.7 ± 2.7 | 4.1 ± 0.1 | 342.7 ± 31.9 | 341.1 ± 25.7 | 34.5 ± 5.4 |
| Beet juice trial | ||||||
| Rest | 64 ± 3 | 87.0 ± 2.3 | 3.8 ± 0.1 | 27.1 ± 2.8 | 31.2 ± 3.0 | 2.6 ± 0.2 |
| 5% MVC | 66 ± 3 | 87.9 ± 2.4 | 3.8 ± 0.1 | 63.5 ± 6.8 | 71.9 ± 6.7 | 7.6 ± 0.8 |
| 15% MVC | 69 ± 3 | 91.6 ± 3.0 | 3.9 ± 0.1 | 183.9 ± 14.9 | 228.3 ± 17.6 | 23.7 ± 2.9 |
| 25% MVC | 73 ± 3 | 97.7 ± 2.9 | 4.0 ± 0.1 | 322.5 ± 27.1 | 329.9 ± 24.3 | 37.6 ± 4.7 |
| 25% MVC + hypoxia | 91 ± 5 | 100.8 ± 3.6 | 4.1 ± 0.1 | 372.9 ± 38.8 | 369.9 ± 31.1 | 37.8 ± 6.0 |
| Control trial | ||||||
| Rest | 59 ± 3 | 90.7 ± 2.6 | 4.0 ± 0.2 | 30.4 ± 2.2 | 41.3 ± 7.2 | 2.3 ± 0.6 |
| 5% MVC | 63 ± 4 | 93.4 ± 3.7 | 4.0 ± 0.2 | 75.0 ± 7.5 | 80.6 ± 7.5 | 8.4 ± 0.3 |
| 15% MVC | 67 ± 4 | 95.4 ± 3.8 | 4.1 ± 0.2 | 197.6 ± 17.9 | 206.8 ± 14.7 | 26.2 ± 2.7 |
| 25% MVC | 73 ± 4 | 99.0 ± 3.6 | 4.3 ± 0.1 | 338.7 ± 35.9 | 340.6 ± 29.1 | 43.8 ± 4.0 |
| 25% MVC + hypoxia | 81 ± 4 | 100.6 ± 4.0 | 4.4 ± 0.2 | 417.9 ± 52.8 | 411.5 ± 38.1 | 54.8 ± 4.9 |
| Placebo trial | ||||||
| Rest | 63 ± 5 | 92.0 ± 1.1 | 4.0 ± 0.2 | 29.5 ± 3.9 | 31.9 ± 3.9 | 3.4 ± 0.5 |
| 5% MVC | 67 ± 5 | 92.2 ± 2.3 | 4.0 ± 0.2 | 75.1 ± 11.0 | 81.3 ± 10.8 | 9.9 ± 1.2 |
| 15% MVC | 69 ± 5 | 93.3 ± 2.1 | 4.1 ± 0.2 | 178.7 ± 23.4 | 192.7 ± 26.0 | 29.5 ± 3.9 |
| 25% MVC | 75 ± 4 | 98.4 ± 2.1 | 4.2 ± 0.1 | 332.5 ± 32.2 | 338.5 ± 32.4 | 46.2 ± 4.3 |
| 25% MVC + hypoxia | 82 ± 5 | 100.7 ± 2.8 | 4.4 ± 0.2 | 419.6 ± 38.2 | 416.6 ± 36.1 | 59.5 ± 5.5 |
P < 0.05 versus control trial in respective condition.
Venous blood gas variables
| pH | PCO2 (mmHg) | PO2 (mmHg) | SO2 (%) | p50 (mmHg) | CtO2 (mL/dL) | |
|---|---|---|---|---|---|---|
| Control trial | ||||||
| Rest | 7.37 ± 0.01 | 47.9 ± 1.9 | 31.0 ± 2.5 | 55.0 ± 5.3 | 26.9 ± 0.6 | 10.7 ± 1.0 |
| 5% MVC | 7.36 ± 0.01 | 50.2 ± 1.6 | 22.7 ± 1.2 | 36.5 ± 3.3 | 26.8 ± 0.4 | 7.3 ± 0.7 |
| 15% MVC | 7.33 ± 0.02 | 55.2 ± 2.3 | 22.8 ± 0.6 | 35.6 ± 1.5 | 26.7 ± 0.5 | 7.1 ± 0.4 |
| 25% MVC | 7.30 ± 0.02 | 59.7 ± 2.9 | 24.6 ± 1.0 | 37.4 ± 2.2 | 26.8 ± 0.6 | 7.5 ± 0.3 |
| 25% MVC + hypoxia | 7.32 ± 0.02 | 55.6 ± 3.0 | 21.9 ± 1.6 | 31.6 ± 3.7 | 27.0 ± 0.5 | 6.8 ± 0.8 |
| Beet juice trial | ||||||
| Rest | 7.36 ± 0.01 | 46.2 ± 1.4 | 27.2 ± 1.6 | 47.7 ± 4.1 | 26.7 ± 0.3 | 9.7 ± 0.8 |
| 5% MVC | 7.36 ± 0.01 | 49.2 ± 2.2 | 22.1 ± 1.3 | 35.0 ± 3.3 | 26.9 ± 0.5 | 7.0 ± 0.7 |
| 15% MVC | 7.32 ± 0.01 | 54.5 ± 2.2 | 22.5 ± 0.9 | 33.9 ± 1.9 | 26.7 ± 0.5 | 6.8 ± 0.3 |
| 25% MVC | 7.29 ± 0.02 | 57.6 ± 3.4 | 25.6 ± 1.2 | 38.9 ± 2.5 | 26.8 ± 0.4 | 7.9 ± 0.4 |
| 25% MVC + hypoxia | 7.31 ± 0.02 | 53.2 ± 2.3 | 21.6 ± 1.2 | 30.7 ± 2.8 | 26.8 ± 0.5 | 6.7 ± 0.6 |
| Control trial | ||||||
| Rest | 7.37 ± 0.01 | 43.6 ± 3.2 | 28.6 ± 2.7 | 48.3 ± 4.5 | 28.6 ± 1.7 | 10.4 ± 0.8 |
| 5% MVC | 7.37 ± 0.01 | 50.2 ± 1.5 | 20.9 ± 0.7 | 35.3 ± 3.4 | 25.5 ± 0.7 | 7.6 ± 0.9 |
| 15% MVC | 7.32 ± 0.01 | 57.5 ± 1.3 | 20.3 ± 0.8 | 29.8 ± 1.6 | 25.8 ± 0.6 | 6.4 ± 0.5 |
| 25% MVC | 7.27 ± 0.01 | 63.4 ± 2.0 | 21.5 ± 0.9 | 30.0 ± 2.0 | 25.9 ± 0.3 | 6.5 ± 0.5 |
| 25% MVC + hypoxia | 7.28 ± 0.01 | 63.0 ± 1.2 | 19.7 ± 0.9 | 24.3 ± 1.7 | 27.1 ± 0.1 | 5.2 ± 0.4 |
| Placebo trial | ||||||
| Rest | 7.34 ± 0.01 | 49.0 ± 1.0 | 21.7 ± 1.3 | 33.6 ± 3.4 | 26.3 ± 0.2 | 7.4 ± 1.0 |
| 5% MVC | 7.34 ± 0.01 | 54.0 ± 0.9 | 20.1 ± 0.3 | 28.0 ± 1.3 | 27.1 ± 0.8 | 5.9 ± 0.6 |
| 15% MVC | 7.30 ± 0.02 | 59.6 ± 1.4 | 20.3 ± 1.0 | 28.5 ± 2.0 | 25.9 ± 0.3 | 6.2 ± 0.4 |
| 25% MVC | 7.30 ± 0.01 | 63.8 ± 1.0 | 21.5 ± 0.8 | 29.0 ± 1.5 | 26.1 ± 0.5 | 6.3 ± 0.4 |
| 25% MVC + hypoxia | 7.26 ± 0.01 | 64.6 ± 1.4 | 18.1 ± 1.7 | 22.6 ± 3.1 | 26.0 ± 1.5 | 4.8 ± 0.6 |
P < 0.05 versus control condition in BR condition.
Ventilation and pulse oximetry in BR and placebo trials
| Ve (L/min) | EtCO2 (mmHg) | SpO2 (%) | |
|---|---|---|---|
| Control trial | |||
| Rest | 8.5 ± 0.7 | 36.3 ± 1.3 | 97.8 ± 0.2 |
| 5% MVC | 8.4 ± 0.7 | 36.3 ± 0.9 | 97.5 ± 0.3 |
| 15% MVC | 9.3 ± 0.5 | 37.3 ± 0.9 | 98.5 ± 0.7 |
| 25% MVC | 11.3 ± 0.7 | 37.1 ± 0.9 | 98.3 ± 0.5 |
| 25% MVC + hypoxia | 26.2 ± 0.2 | 35.8 ± 0.9 | 79.6 ± 0.7 |
| Beet juice trial | |||
| Rest | 9.0 ± 0.6 | 36.9 ± 0.9 | 97.7 ± 0.3 |
| 5% MVC | 9.9 ± 0.5 | 36.7 ± 0.9 | 97.6 ± 0.4 |
| 15% MVC | 10.2 ± 0.5 | 36.7 ± 0.8 | 97.8 ± 0.5 |
| 25% MVC | 12.6 ± 0.8 | 37.1 ± 0.9 | 97.4 ± 0.4 |
| 25% MVC + hypoxia | 31.2 ± 3.8 | 36.7 ± 0.7 | 80.0 ± 0.6 |
| Control trial | |||
| Rest | 9.5 ± 0.9 | 36.1 ± 1.8 | 97.8 ± 0.5 |
| 5% MVC | 9.5 ± 0.8 | 37.1 ± 1.0 | 97.6 ± 0.9 |
| 15% MVC | 10.3 ± 0.6 | 37.2 ± 0.9 | 97.5 ± 0.3 |
| 25% MVC | 11.9 ± 0.7 | 37.1 ± 0.9 | 97.6 ± 0.3 |
| 25% MVC + hypoxia | 31.1 ± 1.4 | 36.9 ± 0.7 | 79.8 ± 0.2 |
| Placebo trial | |||
| Rest | 9.8 ± 0.5 | 35.3 ± 1.1 | 97.8 ± 0.5 |
| 5% MVC | 11.4 ± 0.9 | 35.7 ± 1.0 | 97.5 ± 0.3 |
| 15% MVC | 11.0 ± 0.5 | 35.9 ± 1.0 | 97.3 ± 0.6 |
| 25% MVC | 12.9 ± 1.1 | 35.9 ± 0.9 | 97.3 ± 0.7 |
| 25% MVC + hypoxia | 35.7 ± 1.8 | 36.5 ± 0.8 | 80.4 ± 0.9 |
P < 0.05 versus control condition in respective trial.
Figure 2(A) Plasma Nitrate () and (B) Nitrite () concentrations in control trial and 2–3 h after ingestion of BR (BEET). *P < 0.05 versus control trial.
Figure 3(A) Forearm blood flow and (B) vascular conductance during graded handgrip exercise and hypoxic exercise prior to and following ingestion of concentrated BR (BEET). *P < 0.05 versus control trial within respective condition (BEET or Placebo). % MVC, % of maximal voluntary contraction.
Figure 4(A) Forearm VO2 and (B) a‐vO2 at rest and during graded handgrip exercise and hypoxic exercise prior to and following BR ingestion (BEET). *P < 0.05 versus control trial. % MVC, % of maximal voluntary contraction.